An observational study in Acute Ischemic Stroke, sponsored by Capital Medical University. Status unknown at 1 site in China. Per ClinicalTrials.gov, last updated 2022-01-28.
Sponsored by Capital Medical University · Observational
The Acute Ischemic Stroke Registry for Endovascular Treatment (AIS-EVT) is an academic, prospective, multicenter, observational registry study. Consecutive stroke patients treated with endovascular treatment will be enrolled in stroke centers. Baseline information and clinical follow-up information at 90 days of stroke onset are collected. Data collected include demographics, comorbidities, pathogenesis, blood pressures, stroke severity on admission, time intervals, reperfusion condition, and functional outcome, et al.
2,656 studies on the registry are indexed under Ischemic Stroke; 936 are open to participants now.
This study's planned enrollment of 500 is above the median of 300 across 787 observational studies indexed under Ischemic Stroke.
Browse Ischemic Stroke studies →Capital Medical University is the lead sponsor of 294 studies on the registry; 92 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Acute ischemic stroke patients with large vessel occlusion receiving endovascular treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
No evidence of large vessel occlusion on digital subtraction angiography.
Re-open the occluded cerebral artery using endovascular treatment
The modified Rankin Scale score at 90 days
The range of the modified Rankin Scale is from 0 to 6. A higher score indicates a worse outcome. 0-No symptoms; 1-No significant disability; 2-Slight disability; 3-Moderate disability; 4-Moderately severe disability; 5-Severe disability; 6-Dead.
Time frame: 90 days
This study is status unknown, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.